If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
109.00    1.60 (1.49%)
Bid:
108.60
Ask:
109.00
Spread: 0.40 (0.368%)
Market Cap: £662.93m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Director Declaration

22 Jun 2022 17:21

RNS Number : 8659P
Syncona Limited
22 June 2022
 

Syncona Limited (the "Company")

Director Declaration

 

22 June 2022

In accordance with the requirements of the Listing Rule 9.6.14R, the Company advises the following change to directorships in other publicly quoted companies, held by the following member of the Board:

Virginia Holmes was appointed to Murray International Trust PLC on 22 June 2022.

Enquiries

Syncona Ltd

Andrew Cossar

Tel: +44 (0) 20 3981 7940

 

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758200

 

About Syncona:

Syncona is a leading FTSE250 healthcare company whose purpose is to invest to extend and enhance human life by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Copies of this press release, a company results presentation, and other corporate information can be found on the company website at: www.synconaltd.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNQLLFLLQLLBBB
Date   Source Headline
20th Jul 20207:00 amRNSFreeline files registration statement
13th Jul 20204:51 pmRNSFreeline publishes further data for FLT180a
9th Jul 20201:00 pmRNSIssue of shares pursuant to Incentive Scheme
30th Jun 20207:00 amRNSFreeline announces additional financing plans
30th Jun 20207:00 amRNSFreeline expands Series C financing to $120million
25th Jun 202012:38 pmRNSAnnual Financial Report
18th Jun 202012:45 pmRNSDirector/PDMR Shareholding
15th Jun 20207:00 amRNSKemal Malik Appointed as Non-Executive Director
12th Jun 20207:36 amRNSAutolus AUTO1 and AUTO3 data at EHA
11th Jun 20207:00 amRNSFinal Results
29th May 202012:49 pmRNSAutolus presents additional data on AUTO3 in DLBCL
29th May 20207:05 amRNSFirst patient dosed in Achilles’ melanoma study
20th May 20209:24 amRNSNotice of Results
7th May 202012:15 pmRNSAutolus reports Q1 2020 Financial Results
23rd Apr 20207:00 amRNSNew commitment to SwanBio
16th Apr 202012:10 pmRNSAutolus announces acceptance of IND application
31st Mar 20201:26 pmRNSDirector/PDMR Shareholding
26th Mar 20209:41 amRNSStandard form for notification of major holdings
23rd Mar 20207:00 amRNSBusiness Update
20th Mar 20204:44 pmRNSSecond Price Monitoring Extn
20th Mar 20204:39 pmRNSPrice Monitoring Extension
20th Mar 20201:53 pmRNSDirector/PDMR Shareholding
5th Mar 202011:14 amRNSDirector/PDMR Shareholding
3rd Mar 202012:29 pmRNSAutolus reports Q4 2019 Financial Results
12th Feb 20202:00 pmRNSFreeline presents clinical data at WORLDSymposium
7th Feb 20201:24 pmRNSFreeline publishes further data for FLT180a
4th Feb 20207:00 amRNSQuarterly Update
30th Jan 202012:08 pmRNSAutolus announces additional data in AUTO3 at EHA
23rd Jan 20207:00 amRNSAutolus announces pricing of public offering
21st Jan 202012:01 pmRNSFreeline to present further FLT180a data at EAHAD
21st Jan 20208:45 amRNSNotice of Capital Markets Day
19th Dec 20197:00 amRNSSyncona makes further $80m commitment to Freeline
9th Dec 20197:00 amRNSAutolus announces new data at ASH Annual Meeting
9th Dec 20197:00 amRNSAutolus announces new data in AUTO3 at ASH
21st Nov 20197:00 amRNSSyncona leads £32 million financing in Azeria
21st Nov 20197:00 amRNSInterim Results
11th Nov 20199:00 amRNSNotice of Results
7th Nov 201912:32 pmRNSAutolus reports Q3 2019 Financial Results
6th Nov 20192:20 pmRNSAutolus to Present New Data at the ASH Meeting
6th Nov 20192:13 pmRNSFreeline presents pre-clinical data at ASH meeting
3rd Sep 20197:00 amRNSSyncona cornerstones £100m financing in Achilles
3rd Sep 20197:00 amRNSSyncona makes £48 million commitment to Gyroscope
12th Aug 20197:00 amRNSQuarterly Update
8th Aug 201912:59 pmRNSAutolus reports Q2 2019 Financial Results
1st Aug 20197:00 amRNSCompletion of sale of Blue Earth Diagnostics
31st Jul 201912:24 pmRNSTotal Voting Rights
30th Jul 201911:55 amRNSResult of AGM
18th Jul 20193:51 pmRNSIssue of shares per 2019 dividend & PDMR dealings
11th Jul 201911:21 amRNSIssue of shares pursuant to LTIP and PDMR dealings
8th Jul 20197:00 amRNSFreeline provides 12 month Haemophilia B data

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.